10x Genomics, Inc.

NasdaqGS:TXG

Sector

🤖 Technology

Industries

🧬 Biotechnology

🤖 Artificial Intelligence (AI)

🔌 Hardware & Electronics

🩺 Medical Instruments

💻 Semiconductors

Location

United States

Market Cap

USD 1.34 B

Share Price

USD 10.87

Avg Daily Volume

3,594,117

Change (1 day)

2.94%

Change (1 year)

-45.02%

Change (YTD)

-24.30%

10x Genomics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending March 31, 2025: -25.14%

10x Genomics, Inc. Net Income Margin is -25.14% for the Trailing 12 Months (TTM) ending March 31, 2025, a -40.51% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

10x Genomics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -42.26%, a 29.97% change year over year.
10x Genomics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -32.51%, a 82.18% change year over year.
10x Genomics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -17.85%, a -88.86% change year over year.
10x Genomics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -160.22%, a 768.21% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Net Income Margin	EBT Margin	Operating Income Margin	Gross Profit Margin

NasdaqGS: TXG

10x Genomics, Inc.

CEO	Dr. Serge Saxonov Ph.D.
IPO Date	Sept. 12, 2019
Location	United States
Headquarters	6230 Stoneridge Mall Road
Employees	1,306
Sector	🤖 Technology
Industries Biotechnology 🤖 Artificial Intelligence (AI) 🔌 Hardware & Electronics 🩺 Medical Instruments 💻 Semiconductors

Description

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.